RxSight Stock

rxsight.comHealthcareFounded: 1997Funding to Date: $179.84MM

RxSight is the developer of the first and only adjustable intraocular lens (IOL) that is customized after cataract surgery, enabling doctors and patients to predictably optimize vision after cataract surgery through an office based IOL enhancement.

Register for Details

For more details on financing and valuation for RxSight, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Ronald Kurtz MD
Chief Executive Officer, President & Board Member
Shelley Thunen
Chief Financial Officer
Matthew Haller Ph.D
Chief Technology Officer
Eric Weinberg
Chief Commercial Officer
Robert Grubbs
Co-Founder
Christian Sandstedt Ph.D
Vice President, Optics Research & Development

Board Members

Bruce Robertson Ph.D
H.I.G. BioHealth Partners
Christopher Cox JD
Daniel Schwartz
J. Corley
James Adler
Jan Bonel
Javier Perez-Sala
Joseph Devivo
Juliet Bakker
Longitude Capital
Ronald Kurtz MD
Werner Wolfen
William Link Ph.D
Flying L Partners

Other companies like RxSight in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$2.51B
Sector
Last Round Est. Valuation
$1.4B
Sector
Last Round Est. Valuation
$453MM
Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$1.61B
Sector
Last Round Est. Valuation
$355.29MM
Sector
Last Round Est. Valuation
$8.18B
Sector
Last Round Est. Valuation
$263MM

News

Venture investors are providing $69 million to Calhoun Vision Inc. and betting that its technology will make it stand out in a crowded market for artificial lenses used in cataract patients.